Biomarker - Panitumumab Response With KRAS Wild Type MCC

Summary

This is an exploratory study in which all eligible subjects are given Panitumumab according to the dose and schedule approved by Health Canada. The purpose of this research study is to determine whether the presence of certain biomarkers (substances measurable in blood, normal cells or tumour tissue) are associated with an increased or decreased chance of benefit from panitumumab.

Timeline

Start

2009-10

Primary completion

2015-09

Completion

2015-09

Drugs

Indications